Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Summit Therapeutics plc (SUMM) Ordinary Shares 1p

Sell:18.00p Buy:23.00p 0 Change: No change
Market closed Prices as at close on 21 February 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Conversion

Summit Therapeutics plc Ordinary Shares 1p

Type:
Conversion
Shareholder action required:
Yes
Status:
Update Pending
Details (last updated 10 Feb 2020)

What is happening?

 

The Board of Summit Therapeutics plc have announced that the Company will cancel the Company’s Ordinary Shares from trading on AIM (Alternative Investment Market). It is expected that the Company’s Shares will be delisted with effect from the close of business on 21 February 2020.

 

Why is this happening?

 

“The AIM Delisting reflects the increasing focus of the Company’s business operations on the United States.” (Source: Shareholder announcement, 6 December 2019)

 

Can I convert my Ordinary Shares to ADRs?


Shareholders have the option to convert their Ordinary Shares to ADRs (American Depository Receipts) that will continue to trade on NASDAQ in the US. They are currently trading at USD1.65

 

Each ADR represents 5 Summit Therapeutics plc Ordinary Shares, as such the conversion has to take place in multiples of 5 and it is not possible to receive a fraction of an ADR. Any holdings not in multiples of 5 will receive a fractional cash payment. Trades in ADRs will be settled in US Dollars in accordance with our Overseas Stockbroking terms and conditions.

 

If you wish to convert your Ordinary Shares into ADRs you will need to give an instruction before our deadline of noon on Wednesday 19 February 2020.

 

There is no conversion fee up until the delisting of the Shares from AIM. After close of business on 21 February 2020, conversion into ADRs may incur UK stamp duty or stamp duty reserve tax (currently 1.5% of the market value of the Shares converted) and fees of up to USD0.05 per ADR may be levied by Bank of New York Mellon upon conversion.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown Clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter and not on the summary information outlined above.

×
Sell:18.00p
Buy:23.00p
Change: No change
Market closed Prices as at close on 21 February 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Conversion

Summit Therapeutics plc Ordinary Shares 1p

Type:
Conversion
Shareholder action required:
Yes
Status:
Update Pending
Details (last updated 10 Feb 2020)

What is happening?

 

The Board of Summit Therapeutics plc have announced that the Company will cancel the Company’s Ordinary Shares from trading on AIM (Alternative Investment Market). It is expected that the Company’s Shares will be delisted with effect from the close of business on 21 February 2020.

 

Why is this happening?

 

“The AIM Delisting reflects the increasing focus of the Company’s business operations on the United States.” (Source: Shareholder announcement, 6 December 2019)

 

Can I convert my Ordinary Shares to ADRs?


Shareholders have the option to convert their Ordinary Shares to ADRs (American Depository Receipts) that will continue to trade on NASDAQ in the US. They are currently trading at USD1.65

 

Each ADR represents 5 Summit Therapeutics plc Ordinary Shares, as such the conversion has to take place in multiples of 5 and it is not possible to receive a fraction of an ADR. Any holdings not in multiples of 5 will receive a fractional cash payment. Trades in ADRs will be settled in US Dollars in accordance with our Overseas Stockbroking terms and conditions.

 

If you wish to convert your Ordinary Shares into ADRs you will need to give an instruction before our deadline of noon on Wednesday 19 February 2020.

 

There is no conversion fee up until the delisting of the Shares from AIM. After close of business on 21 February 2020, conversion into ADRs may incur UK stamp duty or stamp duty reserve tax (currently 1.5% of the market value of the Shares converted) and fees of up to USD0.05 per ADR may be levied by Bank of New York Mellon upon conversion.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown Clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter and not on the summary information outlined above.

×
Sell:18.00p
Buy:23.00p
Change: No change
Market closed Prices as at close on 21 February 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Conversion

Summit Therapeutics plc Ordinary Shares 1p

Type:
Conversion
Shareholder action required:
Yes
Status:
Update Pending
Details (last updated 10 Feb 2020)

What is happening?

 

The Board of Summit Therapeutics plc have announced that the Company will cancel the Company’s Ordinary Shares from trading on AIM (Alternative Investment Market). It is expected that the Company’s Shares will be delisted with effect from the close of business on 21 February 2020.

 

Why is this happening?

 

“The AIM Delisting reflects the increasing focus of the Company’s business operations on the United States.” (Source: Shareholder announcement, 6 December 2019)

 

Can I convert my Ordinary Shares to ADRs?


Shareholders have the option to convert their Ordinary Shares to ADRs (American Depository Receipts) that will continue to trade on NASDAQ in the US. They are currently trading at USD1.65

 

Each ADR represents 5 Summit Therapeutics plc Ordinary Shares, as such the conversion has to take place in multiples of 5 and it is not possible to receive a fraction of an ADR. Any holdings not in multiples of 5 will receive a fractional cash payment. Trades in ADRs will be settled in US Dollars in accordance with our Overseas Stockbroking terms and conditions.

 

If you wish to convert your Ordinary Shares into ADRs you will need to give an instruction before our deadline of noon on Wednesday 19 February 2020.

 

There is no conversion fee up until the delisting of the Shares from AIM. After close of business on 21 February 2020, conversion into ADRs may incur UK stamp duty or stamp duty reserve tax (currently 1.5% of the market value of the Shares converted) and fees of up to USD0.05 per ADR may be levied by Bank of New York Mellon upon conversion.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown Clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter and not on the summary information outlined above.

×
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Open:
20.50p
Trade high:
19.75p
Year high:
34.00p
Market capitalisation
Market cap.
:
£68.91 million
Previous close:
20.50p
Trade low:
18.00p
Year low:
19.00p
P/E ratio:
2.28
Previous:
0.30p (1.44%)
Previous:
0.30p
Volume:
268,382
Dividend yield:
n/a
EMS:
3,000
Data delayed by at least 15 minutes.

Performance

Not available for this stock.

Fundamental data

Year ending: 31/01/2019 31/01/2018
Revenue (£m) 43.01 25.42
Profit before tax (£m) 5.03 (10.89)
Adjusted EPS (p): 9.00 (11.00)
P/E ratio 2.40 n/a
PEG n/a n/a
EPS growth (%) n/a n/a

Values are quoted in the stock's local currency: British pound

All fundamental data

Dividend information for this stock is not available.

Dividend information for this stock is not available.

Ready to invest?

To buy shares in , you'll need to have an account. Try our handy filter to explore the different options.

Compare accounts

Ready to take your first step?

To invest in , you'll need to open an account.
Try our handy filter to find which one suits you best.

Compare accounts

Important Documents

There are no documents available for this stock.

Broker forecasts

Broker recommendations for this stock are not available.

Time / date Time Buy / sell Type Volume Price Value
×

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled ‘N/A’.

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Prices provided by NBTrader. Charts provided by Factset. 'Broker forecast' and 'Recent trades' provided by MoneyAM. News and fundamental data provided by Digital Look.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.